I take a different tack on this Wolfer. I was here when the big deal was NeoPulse, Remember that one? A chemotherapy treatment with electro therapy. At that time Punit was looking at buyout with simply that. Then along came ImmunoPulse. Looking for a buyout. And then along came Dr. Pierce and the greatest unmet need of turning nonresponders into responders. That changes everything for their business plan. I really don't think they're looking for a near-term buyout situation at all. What Merck gets out of this is they find their golden goose to be able to reach more patients with their drug, which increases their revenue dramatically and not only just with Keytruda, but any othercancer indication they're working in and wish to license immunoPulse for. They get a hell of a deal out of this arrangement when it comes to their revenue made from the greater population of nonresponders buying & responding to their drugs. OncoSec is more in the driver than can you give them credit for--at least if this trial proves out like I hope it will.
Think about it. If this collaboration works out it puts Oncosec in the driver seat to every single drug company and not only their PD – ones, but also targeting CD eight, CD 4, T cell drugs and any other drug that at present, or in development, that have a non-responding population in their patient cohort. The potential here is huge for Oncosec in the area of multiple licensing agreements. The golden egg was once thought to be a buyout – – but now it's multiple licensing arrangements with multiple companies with multiple drugs. That's why Punit said, "We look to be industry leaders in the treatment of solid tumor indications."
